Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?

The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of electrocardiology 2017-11, Vol.50 (6), p.825-827
1. Verfasser:	Mason, Jay W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers - analysis Cardiology Cardiovascular disease Drug Evaluation, Preclinical - methods Electrocardiography Heart Conduction System - drug effects hERG channel Humans Ion Channels - drug effects Long QT Syndrome - chemically induced Long QT Syndrome - diagnosis Predictive Value of Tests Proarrhythmia QT prolongation Risk Assessment Torsades de pointes Torsades de Pointes - chemically induced Torsades de Pointes - diagnosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) commercialization of the testing methods, (4) quantitative understanding of arrhythmia risk of the 6 non-hERG channels being tested, (5) validity of the CiPA drug list, and (6) ultimate clinical validation.
ISSN:	0022-0736 1532-8430
DOI:	10.1016/j.jelectrocard.2017.08.011